Genmab A/S

Total Valuation

Genmab A/S carries a market capitalization of 20.63B, placing it among publicly traded companies globally. Its enterprise value stands at 14.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Genmab A/S currently has 62.35M shares outstanding.

Valuation Ratios

Genmab A/S trades at a trailing price-to-earnings ratio of 141.43. The price-to-sales ratio is 26.98, and the price-to-book ratio stands at 1.88.

Enterprise Valuation

On an enterprise value basis, Genmab A/S trades at an EV/EBITDA multiple of 10.49 and an EV/FCF ratio of 13.05. The EV/Sales ratio of 3.63 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.23 provides insight into valuation relative to core operating earnings.

Financial Position

Genmab A/S maintains a current ratio of 2.46, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 88.52, indicating elevated leverage, while an interest coverage ratio of 5.31 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Genmab A/S posts a return on equity of 14.00 and a return on invested capital of 13.88.

Taxes

Over the trailing twelve months, Genmab A/S has paid 118.00M in income taxes, reflecting an effective tax rate of 13.02.

Stock Price Statistics

Genmab A/S's stock has gained approximately 22.00436% over the past 52 weeks. The 50-day moving average sits at 30.27, while the 200-day moving average is 29.33.

Income Statement

Over the trailing twelve months, Genmab A/S generated 4.13B in revenue and converted that into 788.00M in net income, yielding earnings per share of 1.26. EBITDA reached 1.43B, while operating income came in at 1.33B.

Balance Sheet

Genmab A/S holds 1.50B in cash and equivalents against 5.27B in total debt, resulting in a net debt position of 3.63B. Total book value stands at 5.96B, with working capital of 1.66B providing operational flexibility.

Cash Flow

Genmab A/S produced 891.00M in operating cash flow over the past twelve months. After subtracting -23.00M in capital expenditures, free cash flow totaled 868.00M - equivalent to 1.40 per share.

Margins

Genmab A/S operates with a gross margin of 93.03, reflecting its pricing power and cost economics. The operating margin of 32.29 and net profit margin of 19.08 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Genmab A/S's most recent stock split took place on May 1, 2018 with a 1:5 split ratio.

Scores

Genmab A/S posts an Altman Z-Score of 6.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.